Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Phraction Management LLC

Phraction Management LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,164 shares of the medical research company's stock after buying an additional 2,037 shares during the quarter. Thermo Fisher Scientific accounts for approximately 5.0% of Phraction Management LLC's investment portfolio, making the stock its 4th largest position. Phraction Management LLC's holdings in Thermo Fisher Scientific were worth $15,010,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth $25,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Cassady Schiller Wealth Management LLC grew its stake in Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after acquiring an additional 33 shares in the last quarter. Finally, VSM Wealth Advisory LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $36,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded down $0.05 during trading hours on Thursday, hitting $427.71. 739,719 shares of the stock traded hands, compared to its average volume of 1,965,058. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The stock has a market capitalization of $161.46 billion, a price-to-earnings ratio of 25.08, a P/E/G ratio of 2.24 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The firm's 50 day moving average price is $409.06 and its 200-day moving average price is $481.30.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.11 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Wall Street Analyst Weigh In

Several research analysts have commented on TMO shares. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. UBS Group lowered their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Royal Bank Of Canada dropped their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Finally, Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $604.05.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.